Contract manufacturing partnerships market insights cost effective outsourcing, tech integration in robotics/AI, and service portfolio growth. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Contract Manufacturing Partnerships (CMOs) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Contract Manufacturing Partnerships (CMOs) Market, by Service Type
8.1.1. Active Pharmaceutical Ingredient (API) Manufacturing
8.1.1.1. Market Revenue and Forecast
8.1.2. Finished Dosage Formulation (FDF) Manufacturing
8.1.2.1. Market Revenue and Forecast
8.1.3. Packaging Services
8.1.3.1. Market Revenue and Forecast
8.1.4. Analytical and Quality Testing Services
8.1.4.1. Market Revenue and Forecast
8.1.5. Formulation Development
8.1.5.1. Market Revenue and Forecast
8.1.6. Clinical Manufacturing
8.1.6.1. Market Revenue and Forecast
8.1.7. Commercial Manufacturing
8.1.7.1. Market Revenue and Forecast
8.1.8. Technology Transfer & Scale-up
8.1.8.1. Market Revenue and Forecast
8.1.9. Regulatory Compliance Support
8.1.9.1. Market Revenue and Forecast
9.1. Contract Manufacturing Partnerships (CMOs) Market, by Drug Type
9.1.1. Small Molecule Drugs
9.1.1.1. Market Revenue and Forecast
9.1.2. Biologics
9.1.2.1. Market Revenue and Forecast
9.1.3. Highly Potent APIs (HPAPIs)
9.1.3.1. Market Revenue and Forecast
9.1.4. Controlled Substances
9.1.4.1. Market Revenue and Forecast
10.1. Contract Manufacturing Partnerships (CMOs) Market, by Business Model
10.1.1. Fee-for-Service (FFS)
10.1.1.1. Market Revenue and Forecast
10.1.2. Full-Service/Integrated Model (End-to-End Solutions)
10.1.2.1. Market Revenue and Forecast
10.1.3. Co-development & Risk-Sharing Partnerships
10.1.3.1. Market Revenue and Forecast
10.1.4. Dedicated Facility Partnerships (Long-Term Contractual Models)
10.1.4.1. Market Revenue and Forecast
11.1. Contract Manufacturing Partnerships (CMOs) Market, by Scale of Operation
11.1.1. Preclinical & Clinical Phase Manufacturing
11.1.1.1. Market Revenue and Forecast
11.1.2. Commercial-Scale Manufacturing
11.1.2.1. Market Revenue and Forecast
11.1.3. Pilot-Scale / Bridge Manufacturing
11.1.3.1. Market Revenue and Forecast
12.1. Contract Manufacturing Partnerships (CMOs) Market, by End User
12.1.1. Pharmaceutical Companies (Branded & Generic)
12.1.1.1. Market Revenue and Forecast
12.1.2. Biotechnology Companies
12.1.2.1. Market Revenue and Forecast
12.1.3. Nutraceutical Firms
12.1.3.1. Market Revenue and Forecast
12.1.4. Medical Device Manufacturers
12.1.4.1. Market Revenue and Forecast
12.1.5. Academic Institutions & Research Institutes
12.1.5.1. Market Revenue and Forecast
13.1. Contract Manufacturing Partnerships (CMOs) Market, by Therapeutic Area
13.1.1. Oncology
13.1.1.1. Market Revenue and Forecast
13.1.2. Cardiovascular
13.1.2.1. Market Revenue and Forecast
13.1.3. Neurology
13.1.3.1. Market Revenue and Forecast
13.1.4. Infectious Diseases
13.1.4.1. Market Revenue and Forecast
13.1.5. Metabolic Disorders
13.1.5.1. Market Revenue and Forecast
13.1.6. Autoimmune & Inflammatory Diseases
13.1.6.1. Market Revenue and Forecast
13.1.7. rare & orphan diseases
13.1.7.1. Market Revenue and Forecast
13.1.8. Others (Dermatology, Ophthalmology, Urology)
13.1.8.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Service Type
14.1.2. Market Revenue and Forecast, by Drug Type
14.1.3. Market Revenue and Forecast, by Business Model
14.1.4. Market Revenue and Forecast, by Scale of Operation
14.1.5. Market Revenue and Forecast, by End User
14.1.6. Market Revenue and Forecast, by Therapeutic Area
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Service Type
14.1.7.2. Market Revenue and Forecast, by Drug Type
14.1.7.3. Market Revenue and Forecast, by Business Model
14.1.7.4. Market Revenue and Forecast, by Scale of Operation
14.1.8. Market Revenue and Forecast, by End User
14.1.8.1. Market Revenue and Forecast, by Therapeutic Area
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Service Type
14.1.9.2. Market Revenue and Forecast, by Drug Type
14.1.9.3. Market Revenue and Forecast, by Business Model
14.1.9.4. Market Revenue and Forecast, by Scale of Operation
14.1.10. Market Revenue and Forecast, by End User
14.1.11. Market Revenue and Forecast, by Therapeutic Area
14.2. Europe
14.2.1. Market Revenue and Forecast, by Service Type
14.2.2. Market Revenue and Forecast, by Drug Type
14.2.3. Market Revenue and Forecast, by Business Model
14.2.4. Market Revenue and Forecast, by Scale of Operation
14.2.5. Market Revenue and Forecast, by End User
14.2.6. Market Revenue and Forecast, by Therapeutic Area
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Service Type
14.2.8.2. Market Revenue and Forecast, by Drug Type
14.2.8.3. Market Revenue and Forecast, by Business Model
14.2.9. Market Revenue and Forecast, by Scale of Operation
14.2.10. Market Revenue and Forecast, by End User
14.2.10.1. Market Revenue and Forecast, by Therapeutic Area
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Service Type
14.2.11.2. Market Revenue and Forecast, by Drug Type
14.2.11.3. Market Revenue and Forecast, by Business Model
14.2.12. Market Revenue and Forecast, by Scale of Operation
14.2.13. Market Revenue and Forecast, by End User
14.2.14. Market Revenue and Forecast, by Therapeutic Area
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Service Type
14.2.15.2. Market Revenue and Forecast, by Drug Type
14.2.15.3. Market Revenue and Forecast, by Business Model
14.2.15.4. Market Revenue and Forecast, by Scale of Operation
14.2.16. Market Revenue and Forecast, by End User
14.2.16.1. Market Revenue and Forecast, by Therapeutic Area
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Service Type
14.2.17.2. Market Revenue and Forecast, by Drug Type
14.2.17.3. Market Revenue and Forecast, by Business Model
14.2.17.4. Market Revenue and Forecast, by Scale of Operation
14.2.18. Market Revenue and Forecast, by End User
14.2.18.1. Market Revenue and Forecast, by Therapeutic Area
14.3. APAC
14.3.1. Market Revenue and Forecast, by Service Type
14.3.2. Market Revenue and Forecast, by Drug Type
14.3.3. Market Revenue and Forecast, by Business Model
14.3.4. Market Revenue and Forecast, by Scale of Operation
14.3.5. Market Revenue and Forecast, by End User
14.3.6. Market Revenue and Forecast, by Therapeutic Area
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Service Type
14.3.7.2. Market Revenue and Forecast, by Drug Type
14.3.7.3. Market Revenue and Forecast, by Business Model
14.3.7.4. Market Revenue and Forecast, by Scale of Operation
14.3.8. Market Revenue and Forecast, by End User
14.3.9. Market Revenue and Forecast, by Therapeutic Area
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Service Type
14.3.10.2. Market Revenue and Forecast, by Drug Type
14.3.10.3. Market Revenue and Forecast, by Business Model
14.3.10.4. Market Revenue and Forecast, by Scale of Operation
14.3.11. Market Revenue and Forecast, by End User
14.3.11.1. Market Revenue and Forecast, by Therapeutic Area
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Service Type
14.3.12.2. Market Revenue and Forecast, by Drug Type
14.3.12.3. Market Revenue and Forecast, by Business Model
14.3.12.4. Market Revenue and Forecast, by Scale of Operation
14.3.12.5. Market Revenue and Forecast, by End User
14.3.12.6. Market Revenue and Forecast, by Therapeutic Area
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Service Type
14.3.13.2. Market Revenue and Forecast, by Drug Type
14.3.13.3. Market Revenue and Forecast, by Business Model
14.3.13.4. Market Revenue and Forecast, by Scale of Operation
14.3.13.5. Market Revenue and Forecast, by End User
14.3.13.6. Market Revenue and Forecast, by Therapeutic Area
14.4. MEA
14.4.1. Market Revenue and Forecast, by Service Type
14.4.2. Market Revenue and Forecast, by Drug Type
14.4.3. Market Revenue and Forecast, by Business Model
14.4.4. Market Revenue and Forecast, by Scale of Operation
14.4.5. Market Revenue and Forecast, by End User
14.4.6. Market Revenue and Forecast, by Therapeutic Area
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Service Type
14.4.7.2. Market Revenue and Forecast, by Drug Type
14.4.7.3. Market Revenue and Forecast, by Business Model
14.4.7.4. Market Revenue and Forecast, by Scale of Operation
14.4.8. Market Revenue and Forecast, by End User
14.4.9. Market Revenue and Forecast, by Therapeutic Area
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Service Type
14.4.10.2. Market Revenue and Forecast, by Drug Type
14.4.10.3. Market Revenue and Forecast, by Business Model
14.4.10.4. Market Revenue and Forecast, by Scale of Operation
14.4.11. Market Revenue and Forecast, by End User
14.4.12. Market Revenue and Forecast, by Therapeutic Area
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Service Type
14.4.13.2. Market Revenue and Forecast, by Drug Type
14.4.13.3. Market Revenue and Forecast, by Business Model
14.4.13.4. Market Revenue and Forecast, by Scale of Operation
14.4.13.5. Market Revenue and Forecast, by End User
14.4.13.6. Market Revenue and Forecast, by Therapeutic Area
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Service Type
14.4.14.2. Market Revenue and Forecast, by Drug Type
14.4.14.3. Market Revenue and Forecast, by Business Model
14.4.14.4. Market Revenue and Forecast, by Scale of Operation
14.4.14.5. Market Revenue and Forecast, by End User
14.4.14.6. Market Revenue and Forecast, by Therapeutic Area
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Service Type
14.5.2. Market Revenue and Forecast, by Drug Type
14.5.3. Market Revenue and Forecast, by Business Model
14.5.4. Market Revenue and Forecast, by Scale of Operation
14.5.5. Market Revenue and Forecast, by End User
14.5.6. Market Revenue and Forecast, by Therapeutic Area
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Service Type
14.5.7.2. Market Revenue and Forecast, by Drug Type
14.5.7.3. Market Revenue and Forecast, by Business Model
14.5.7.4. Market Revenue and Forecast, by Scale of Operation
14.5.8. Market Revenue and Forecast, by End User
14.5.8.1. Market Revenue and Forecast, by Therapeutic Area
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Service Type
14.5.9.2. Market Revenue and Forecast, by Drug Type
14.5.9.3. Market Revenue and Forecast, by Business Model
14.5.9.4. Market Revenue and Forecast, by Scale of Operation
14.5.9.5. Market Revenue and Forecast, by End User
14.5.9.6. Market Revenue and Forecast, by Therapeutic Area
15.1. Lonza Group
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Catalent Inc.
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Thermo Fisher Scientific (Patheon)
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Samsung Biologics
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Siegfried Holding AG
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Boehringer Ingelheim BioXcellence
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Piramal Pharma Solutions
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Fujifilm Diosynth Biotechnologies
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. CordenPharma
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Curia Global
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description